Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

NCT07160725 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07160725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07160725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 15, 2025
Completion date
August 1, 2028
Enrollment
540 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours